Allogeneic Mesenchymal Stem Cells (MSCs) Archives

Incyte’s Jakafi Hits Mark in Phase III GVHD Trial

Allogeneic Mesenchymal Stem Cells (MSCs), Clinical Data, Clinical Trials, Graft Versus Host Disease (GVHD), Overall Response Rate (ORR), Primary Endpoints, R&D, Secondary Endpoints, Therapeutics

Wilmington, Delaware-based Incyte Corporation announced data from the Phase III REACH3 trial of Jakafi (ruxolitinib) in patients with moderate or severe steroid-refractory or steroid dependent chronic graft-versus-host disease (GVHD).

July 23, 2020/by BioSpace

Celltex Plans to Launch Program to Use Mesenchymal Stem Cells for COVID-19-related Symptoms Under an Existing Regulatory Study

Allogeneic Mesenchymal Stem Cells (MSCs), Autologous Mesenchymal Stem Cells (MSCs), Business, Coronavirus Disease 2019 (COVID-19), Partnerships, R&D

Celltex Therapeutics Corporation began active discussions with the FDA regarding a study using using adult, autologous Mesenchymal Stem Cells against coronavirus (COVID-19)-type symptoms.

March 16, 2020/by Business Wire